Science Corporation raises $230M Series C at $1.5B valuation — claims race to be first BCI product on market
Summary
Science Corporation, co-founded by Neuralink co-founder Max Hodak, raised $230 million in a Series C led by Khosla Ventures at a $1.5 billion post-money valuation. In the near term, Science Corp is focusing on PRIMA — a chip smaller than a grain of rice that, when implanted in the eye, works with camera-equipped glasses to restore functional vision to people with advanced macular degeneration. The company has submitted a CE mark application and expects EU approval in mid-2026, with Germany as its first market, claiming this could make it the first BCI company with a product commercially available.
Why it matters
Science Corp's claim of being the first BCI company to reach market — ahead of Neuralink and Synchron — rests on the PRIMA retinal implant getting CE mark by mid-2026. If successful, this would be a landmark commercial moment for the entire BCI industry, proving that brain-computer interfaces can be regulated, manufactured and sold to patients.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial